Trigeminal Neuralgia (TN) Treatment Market Application and Region —Forecast till 2029

Trigeminal neuralgia (TN) causes inflammatory conditions such as autoimmune disorders like Lyme disease, sarcoidosis, and multiple sclerosis. The increasing prevalence of TN among the growing geriatric population around the world is contributing to the growth of the trigeminal neuralgia treatment market.

Get PDF Sample Reports: https://straitsresearch.com/report/global-trigeminal-neuralgia-treatment-market/request-sample

TN usually affects people older than 50 (American Association of Neuromuscular & Electrodiagnostic Medicine Organization)
The incidence of TN is 12 per 100,000 persons annually (International Association for the Study of Pain)
An estimated 150,000 people are diagnosed with TN every year (American Association of Neurological Surgeons)
The incidence of new TN cases is approximately 12 per 100,000 people per year, as per the National Institute of Neurological Disorders and Strokes (NINDS) 2018 report

Research regarding the care of rare neurological disorders has been making advances. In line with this, the demand for technologically sophisticated tools for the storage and analysis of patient data and rapid integration is rising. Artificial intelligence, machine learning, digital biomedical biomarkers, and computational biology are expected to create opportunities enabling precise diagnosis and treatment.

Full Detail Of This Report: https://straitsresearch.com/report/global-trigeminal-neuralgia-treatment-market/

Several pharmaceutical companies are significantly investing in TN treatment, and regulatory agencies have fastened the drug approval process for new biologics in TN treatment. During the forecast period, the existence of a robust pipeline and the acceptance of new medicines will fuel the development of the global trigeminal neuralgia treatment market. At present, industry players are focusing on innovative products that remove the need for medication and surgery in chronic pain due to TN. For example, PainShield (NanoVibronix) transmits slow-release ultrasound to provide immediate pain relief for injury to the nerves and soft tissues; it is highly effective for TN pain relief and care.

Key Players

GlaxoSmithKline plc
Pfizer Inc.
Trigemina, Inc.
Novartis Pharmaceuticals Corporation
Sun Pharmaceutical Industries Ltd.
Lupin Pharmaceuticals, Inc.
Apotex Inc.
Reddy’s Laboratories
Biogen

Trigeminal Neuralgia Treatment Market: Segmentation

By Treatment Type

Drugs
Carbamazepine
Oxcarbazepine
Others
Surgeries
Microvascular decompression
Stereotactic radiosurgery
Percutaneous procedures

By Treatment Provider

Hospitals and clinics
Ambulatory surgery centres
Others

Increasing Healthcare Expenditure, Rising R&D Investments, and a Large Geriatric Population Foster the Trigeminal Neuralgia Treatment Market in Latin America and the Caribbean

In Latin America and the Caribbean, an estimated 71 million people are aged 60 and older, representing 11.2% of the population. The figure is expected to rise to around 100.5 million by 2025 and some 183.7 million by 2050, as per the estimations by the Latin American and Caribbean Demographic Centre (CELADE). Increasing healthcare expenditure, rising R&D investments, and a better understanding of the nature of rare neurological disorders are all driving market development in the region.

Contact Us
Office C & D - 4th Floor, Siddhi Towers, NIBM Road, Pune 411048,
Maharashtra, India.

Phone
+1 646 480 7505 (U.S.)
+91 8087085354 (India)
+44 208 068 9665 (U.K.)

Mail Id: sales@straitsresearch.com

Regardless of whether you're looking at business sectors in the next town or crosswise over continents, we understand the significance of being acquainted with what customers purchase. We overcome the issues of our customers by recognizing and deciphering just the target group, while simultaneously generating leads with the highest precision. We seek to collaborate with our customers to deliver a broad spectrum of results through a blend of market and business research approaches. This approach of using various research and analysis strategies enable us to determine greater insights by eliminating the research costs. Moreover, we're continually developing, not only with regards to where we measure, or who we measure but in how our visions can enable you to drive cost-effective growth.

This release was published on openPR.